Concepedia

Michael Lewis

ML

Statistics

Publications

9

Citations

318

H-Index

9

Active since

2017

Affiliations

Sage Therapeutics (United States)(Current)

Washington University in St. Louis

Hope Center for Neurological Disorders

Michael Lewis is an author at Sage Therapeutics (United States) specializing in neuroscience, neuropharmacology, and pharmacology.

ORCID

Publications per year

2017–2024

9

Publications

9

25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner

Man Ying Wong, Michael Lewis, James Doherty et al. · Journal of Neuroinflammation · 2020 · 118 citations · Full text

, , +12

Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis

Natasha Warikoo, Samuel J. Brunwasser, Ann Benz et al. · Journal of Neuroscience · 2018 · 52 citations · Full text

, , +17

SAGE-718: A First-in-Class<i>N</i>-Methyl-<scp>d</scp>-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment

Matthew D. Hill, María‐Jesús Blanco, Francesco G. Salituro et al. · Journal of Medicinal Chemistry · 2022 · 41 citations · Full text

, , +14

The synthetic neuroactive steroid SGE-516 reduces seizure burden and improves survival in a Dravet syndrome mouse model

Nicole A. Hawkins, Michael Lewis, Rebecca Hammond et al. · Scientific Reports · 2017 · 34 citations · Full text

, , +15

Neuron-Glia Crosstalk Plays a Major Role in the Neurotoxic Effects of Ketamine via Extracellular Vesicles

Donald H. Penning, Simona Cazacu, Aharon Brodie et al. · Frontiers in Cell and Developmental Biology · 2021 · 19 citations · Full text

, , +17

1–5 of 9